10-K/A: EOS Inc. Files Amended 10-K, Clarifies Subsidiary Roles and Financial Controls

EOS Inc. has filed an amendment to its 2023 annual report to clarify subsidiary roles, management responsibilities, auditor details, and risk factors related to Hong Kong operations.

Summary

• EOS Inc. filed an amendment to its 2023 annual report on Form 10-K to provide additional clarity on several key areas.
• The amendment clarifies the roles of its subsidiaries, including Emperor Star International Trade Co., LTD, EOS International Inc., and EOS Inc., Taiwan Branch, and their contributions to the company's revenue.
• It also clarifies the roles of Zongjiang He and He-Sing Yang in relation to their roles as CO and acting CFO.
• The company's auditors are based in Singapore and are inspected by the PCAOB.
• The amendment addresses the ability of investors to effectuate service of process and enforceable judgments against the company.
• Additional risk factors regarding the company's subsidiary doing business with customers based in Hong Kong have been added.
• The company's revenue decreased by 55% to $296,852 in 2023, compared to $652,547 in 2022, primarily due to decreased consumer demand and phasing out of some older products.
• Gross profit increased to 65% of net sales in 2023, compared to 44% in 2022, due to higher margin nutrition supplement sales.
• The company's net loss improved to $631,936 in 2023, compared to a net loss of $1,912,159 in 2022, due to no significant impairments in assets being recorded.
• The company had a working capital deficit of $1,006,911 as of December 31, 2023.
• The company's auditors have issued a going concern opinion, indicating substantial doubt about its ability to continue as an ongoing business without additional capital or sufficient revenue generation.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a substantial revenue decline, a working capital deficit, and a going concern warning from auditors. While there are some positive aspects, such as improved gross profit margins and reduced losses, the overall sentiment is negative due to the company's precarious financial position and operational risks.

Positives

• The company's gross profit margin increased significantly to 65% in 2023.
• The company's net loss improved by 67% in 2023 compared to 2022.
• The company reversed some provision for doubtful debts, resulting in other income of $147,532.
• The company reduced its selling, general and administrative expenses by 56% in 2023.
• The company reduced its cash used in investing activities.

Negatives

• The company's revenue decreased by 55% in 2023.
• The company has a significant working capital deficit of $1,006,911.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company's cash used in operating activities increased in 2023.
• The company has material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on generating revenues and raising capital.
• The company relies on third-party manufacturers and suppliers, which presents risks related to supply availability and contract renewals.
• The company faces competition from larger companies with greater resources.
• The company's operations are primarily based in Hong Kong, which is subject to political and legal uncertainties.
• The company may face difficulties in enforcing legal judgments and service of process in China and Hong Kong.
• The company has material weaknesses in its internal controls over financial reporting.
• The company's revenue is susceptible to any incidents or factors which affect the stability of the social, economic and political conditions in Hong Kong.
• The Chinese government exerts substantial influence over all business activities conducted in China and may intervene or influence the company's operations at any time with little advance notice.

Future Outlook

The company intends to generate sufficient revenue and raise additional funds to support its operations, but there are no assurances to that effect. The company plans to focus on first-tier cities in China and develop online shopping centers in Southeast Asia starting in the second quarter of 2024.

Management Comments

• Management has financed its operating costs with loans from director and officers.
• Management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel and excessive reliance on third party consultants for accounting, financial reporting and related activities.
• The Management have decided to not elect the definition of fair value as per ASC 718, Compensation Stock Compensation as it believes it is not a fair representation of the value of the Company's stocks.

Industry Context

The company operates in the nutritional supplement market, which is expected to grow significantly. However, the company faces competition from larger, more established players. The company's focus on ginsenoside supplements and its patented technology may provide a competitive advantage.

Comparison to Industry Standards

• The company's revenue decline of 55% is significantly worse than the expected growth in the nutritional food market, which is projected to have a CAGR of 7% over the forecast period.
• The company's gross profit margin of 65% is relatively high compared to some distributors, but it is important to note that the company does not own manufacturing facilities and relies on third-party suppliers.
• The company's net loss, while improved, is still significant and indicates financial challenges. Many companies in the nutritional supplement space are profitable, indicating that EOS Inc. is underperforming its peers.
• The company's working capital deficit and going concern warning are significant red flags, indicating that the company is in a precarious financial position compared to industry standards.
• The company's reliance on related party loans is not uncommon for small companies, but it also indicates a lack of access to traditional financing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• The company has advanced funds from its directors and shareholders Yu Cheng Yang for working capital purposes.
• As of December 31, 2023, there was $74,065 outstanding due to shareholders.
• The company issued 345,000,000 shares of Common Stock to Co-Innovation Group Limited to convert outstanding debt owed to Mr. Yu-Cheng YANG in the amount of $420,900.
• The company issued 55,000,000 shares of Common Stock to non-employees to convert outstanding debt owed to Mr. Yu-Cheng YANG in the amount of $67,100.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and going concern warning.
• Employees may be affected by potential cost-cutting measures or the company's inability to continue operations.
• Customers may experience disruptions in product availability or service quality.
• Suppliers may face risks related to payment delays or the company's potential bankruptcy.
• Creditors face risks related to the company's ability to repay its debts.

Next Steps

• The company plans to focus on first-tier cities in China and develop online shopping centers in Southeast Asia starting in the second quarter of 2024.
• The company intends to generate sufficient revenue and raise additional funds to support its operations.

Key Dates

Keywords

Ginsenosides, Nutritional Supplements, Hong Kong, Taiwan, Financial Reporting, Internal Controls, Going Concern, Debt Conversion, Revenue, OTC, Distribution, Consumer Products